Nadine Tung

24PUBLICATIONS
182CO-AUTHORS
Molecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRespiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 07, 2026
Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy.

|Feb 28, 2026
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2.

Adriana I Apostol, Jacek Gronwald, Cezary Cybulski

|Jan 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Nadine M Tung, Mark E Robson, Tianyu Li

|Oct 02, 2024
Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2.

Kelly-Anne Phillips, Joanne Kotsopoulos, Susan M Domchek

|Jul 19, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).

Adrienne G Waks, Emily L Chen, Noah Graham

|Jun 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

Pageof 4

Frequent Collaborators

8 joint publications

Eric P Winer

6 joint publications

Sara M Tolaney

6 joint publications

Ian Krop

5 joint publications

Nabihah Tayob